JP2001517080A - キメラアデノウイルスコート蛋白質およびその使用方法 - Google Patents
キメラアデノウイルスコート蛋白質およびその使用方法Info
- Publication number
- JP2001517080A JP2001517080A JP53987998A JP53987998A JP2001517080A JP 2001517080 A JP2001517080 A JP 2001517080A JP 53987998 A JP53987998 A JP 53987998A JP 53987998 A JP53987998 A JP 53987998A JP 2001517080 A JP2001517080 A JP 2001517080A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- adenovirus
- coat protein
- protein
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C12N2810/405—Vectors comprising RGD peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.非天然アミノ酸配列を含むキメラアデノウイルスコート蛋白質であって、野 生型アデノウイルスコート蛋白質指向性の中和抗体により認識される能力が低下 しているか、あるいは認識され得ない該キメラアデノウイルスコート蛋白質。 2.該非天然アミノ酸配列が、野生型アデノウイルスコート蛋白質の約1〜約7 50アミノ酸の領域の欠失、挿入または置換を含む、請求の範囲1のキメラアデ ノウイルスコート蛋白質。 3.該非天然アミノ酸配列が複数の欠失、挿入および/または置換を含む、請求 の範囲1または2のキメラアデノウイルスコート蛋白質。 4.該コート蛋白質がキメラアデノウイルスヘキソン蛋白質である、請求の範囲 1〜3のいずれかのキメラアデノウイルスコート蛋白質。 5.該欠失または置換された領域が11ループまたは12ループ内の超可変領域 を含む、請求の範囲4のキメラアデノウイルスコート蛋白質。 6.該超可変領域がHVR1、HVR2、HVR3、HVR4、HVR5、HV R6およびHVR7からなる群より選択される、請求の範囲5のキメラアデノウ イルスコート蛋白質。 7.配列番号6、配列番号8、配列番号10、配列番号12、配列番号14、配 列番号16、配列番号18、配列番号20、配列番号22、配列番号24、配列 番号26、配列番号28、配列番号30、配列番号32、配列番号34、配列番 号36、 配列番号38、配列番号40、配列番号42、配列番号44、配列番号46およ び配列番号48からなる群より選択される配列を含む、請求の範囲1〜6のいず れかのキメラアデノウイルスコート蛋白質。 8.該非天然アミノ酸配列が約1〜約750アミノ酸のスペーサーを含む、請求 の範囲1〜7のいずれかのキメラアデノウイルスコート蛋白質。 9.該スペーサーが配列番号50の配列を含む、請求の範囲8のキメラコートア デノウイルス蛋白質。 10.別の血清型のアデノウイルスのコート蛋白質のアミノ酸配列を含む、請求 の範囲1〜9のいずれかのキメラアデノウイルスコート蛋白質。 11.該別の血清型のコート蛋白質がヘキソン蛋白質である、請求の範囲10の キメラアデノウイルスコート蛋白質。 12.請求の範囲1〜11のいずれかのキメラアデノウイルスコート蛋白質をコ ードする単離または精製された核酸。 13.配列番号5、配列番号7、配列番号9、配列番号11、配列番号13、配 列番号15、配列番号17、配列番号19、配列番号21、配列番号23、配列 番号25、配列番号27、配列番号29、配列番号31、配列番号33、配列番 号35、配列番号37、配列番号39、配列番号41、配列番号43、配列番号 45および配列番号47からなる群より選択される配列を含む、請求の範囲12 の単離または精製された核酸。 14.配列番号49の配列を含む、請求の範囲12または13の単離または精製 された核酸。 15.請求の範囲1〜11のいずれかのキメラアデノウイルスコート蛋白質を含 むアデノウイルスベクター。 16.請求の範囲15のアデノウイルスベクターに細胞を接触させることを含む 、該細胞を遺伝学的に改変する方法。 17.請求の範囲1〜11のいずれかのキメラアデノウイルスコート蛋白質を含 む宿主細胞。 18.野生型アデノウイルスコート蛋白質指向性の中和抗体により認識される能 力が低下しているか、あるいは認識され得ないアデノウイルスベクターの構築方 法であって、野生型アデノウイルスコート蛋白質を含むアデノウイルスベクター を取得し、該野生型アデノウイルスコート蛋白質を請求の範囲1〜11のいずれ かのキメラアデノウイルスコート蛋白質で置換することを含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/816,346 US6127525A (en) | 1995-02-21 | 1997-03-13 | Chimeric adenoviral coat protein and methods of using same |
US08/816,346 | 1997-03-13 | ||
PCT/US1998/005033 WO1998040509A1 (en) | 1997-03-13 | 1998-03-13 | Chimeric adenoviral coat protein and methods of using same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001517080A true JP2001517080A (ja) | 2001-10-02 |
JP2001517080A5 JP2001517080A5 (ja) | 2005-11-10 |
Family
ID=25220343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53987998A Pending JP2001517080A (ja) | 1997-03-13 | 1998-03-13 | キメラアデノウイルスコート蛋白質およびその使用方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US6127525A (ja) |
EP (1) | EP0973927A1 (ja) |
JP (1) | JP2001517080A (ja) |
AU (1) | AU745252B2 (ja) |
CA (1) | CA2283628A1 (ja) |
WO (1) | WO1998040509A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009523007A (ja) * | 2004-10-13 | 2009-06-18 | クルセル ホランド ベー ヴェー | 改良されたアデノウイルスベクターおよびその使用方法 |
JP2009136296A (ja) * | 2001-11-21 | 2009-06-25 | Univ Pennsylvania | サルアデノウイルス核酸およびアミノ酸配列、それを含むベクターおよび使用方法 |
JP2009535032A (ja) * | 2006-04-28 | 2009-10-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 改変アデノウイルスヘキソンタンパク質およびその用途 |
JP2012110326A (ja) * | 2004-01-23 | 2012-06-14 | Ist Di Ricerche Di Biologia Molecolare P Angeletti Spa | チンパンジーアデノウイルスワクチン担体 |
JP2018519847A (ja) * | 2015-05-04 | 2018-07-26 | ヴィーシーエヌ、バイオサイエンシズ、ソシエダッド、リミターダVcn Biosciences Sl | 免疫優性アデノウイルスエピトープに突然変異を有する腫瘍溶解性アデノウイルスおよび癌処置におけるそれらの使用 |
JP2021500899A (ja) * | 2017-10-31 | 2021-01-14 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | アデノウイルスベクター及びその用途 |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
IL122614A0 (en) * | 1995-06-15 | 1998-08-16 | Introgene Bv | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US20040043489A1 (en) * | 1998-07-08 | 2004-03-04 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use |
US20030017138A1 (en) * | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
IL141500A0 (en) * | 1998-08-27 | 2002-03-10 | Aventis Pharma Sa | Targeted adenovirus vectors for delivery of heterologous genes |
US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
EP1157999A1 (en) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof |
JP2003534805A (ja) | 2000-05-31 | 2003-11-25 | ユニバーシティ オブ サスカチュワン | 変化した親和性を有する改変ウシアデノウイルス |
US6579522B1 (en) * | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
US20040033605A1 (en) * | 2000-09-20 | 2004-02-19 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells |
DE60138403D1 (de) * | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten |
US6821264B1 (en) | 2000-11-27 | 2004-11-23 | Gautam Khurana | Gene delivery device and gene delivery method |
EP1390476A4 (en) * | 2001-04-17 | 2005-03-30 | Vectorlogics Inc | MOSAIC adenovirus vectors |
US20030219899A1 (en) * | 2001-04-17 | 2003-11-27 | Nikolay Korokhov | Mosaic adenoviral vectors |
US20040136963A1 (en) * | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
US6905678B2 (en) * | 2001-07-07 | 2005-06-14 | Crucell Holland B.V. | Gene delivery vectors with cell type specificity for mesenchymal stem cells |
EP1436397B1 (en) * | 2001-10-11 | 2010-05-12 | Merck Sharp & Dohme Corp. | Hepatitis c virus vaccine |
AU2006204656B2 (en) * | 2001-11-21 | 2008-01-24 | The Trustees Of The University Of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
AU2003210661A1 (en) * | 2002-01-24 | 2003-09-02 | Novartis Ag | Fiber shaft modifications for efficient targeting |
WO2003072703A2 (en) * | 2002-02-05 | 2003-09-04 | Cornell Research Foundation, Inc. | Adenoviral vector with replication-dependent transgene expression |
AU2003271737B2 (en) * | 2002-04-25 | 2007-04-19 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
US20040166091A1 (en) * | 2003-02-24 | 2004-08-26 | Genvec, Inc. | Materials and methods for treating disorders of the ear |
WO2004092397A2 (en) * | 2003-04-15 | 2004-10-28 | Novartis Ag | Tmprss2 regulatory sequences and uses thereof |
WO2004092396A2 (en) * | 2003-04-15 | 2004-10-28 | Novartis Ag | Flap endonuclease 1 (fen1) regulatory sequences and uses thereof |
JP4754480B2 (ja) * | 2003-06-20 | 2011-08-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | キメラアデノウイルスの作成法およびそのようなキメラアデノウイルスの使用 |
US7291498B2 (en) * | 2003-06-20 | 2007-11-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
EP1649028B1 (en) * | 2003-07-25 | 2012-08-22 | Genvec, Inc. | Adenoviral vector-based vaccines |
WO2005030927A2 (en) * | 2003-09-23 | 2005-04-07 | Uab Research Foundation | Methods and compositions for in vivo inflammation monitoring |
ES2340038T3 (es) * | 2003-11-14 | 2010-05-28 | Genvec, Inc. | Composicion farmaceutica para tratar cancer de pancreas localmente avanzado (cpla) no extirpable. |
US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
CA2563396A1 (en) | 2004-04-12 | 2005-11-24 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Method of using adenoviral vectors to induce an immune response |
WO2006008468A2 (en) * | 2004-07-20 | 2006-01-26 | The University Of Warwick | Adenovirus vector and method to manipulate the adenovirus genome |
US20060062764A1 (en) * | 2004-08-25 | 2006-03-23 | Seshidar-Reddy Police | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
CA2589602A1 (en) * | 2004-09-01 | 2006-04-13 | Genvec, Inc. | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
EA010433B1 (ru) * | 2004-10-13 | 2008-08-29 | Круселл Холланд Б.В. | Усовершенствованные аденовирусные векторы и их применение |
US20060205080A1 (en) * | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
AU2006284756B2 (en) * | 2005-08-31 | 2012-06-07 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
US9651543B2 (en) | 2005-08-31 | 2017-05-16 | The United States Of America As Represented By The Secretary Of The Navy | Malaria antigen screening method |
US8450055B2 (en) * | 2005-08-31 | 2013-05-28 | The United States Of America As Represented By The Secretary Of The Navy | Malaria antigen screening method |
EP1951297A2 (en) * | 2005-11-10 | 2008-08-06 | GenVec, Inc. | Adenoviral vector-based foot-and-mouth disease vaccine |
JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ctla−4抗体の限局性分泌のための方法および組成物 |
US7919079B2 (en) * | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
US20090280089A1 (en) * | 2006-06-19 | 2009-11-12 | Institut Gustave Roussy | Inhibition of the liver tropism of adenoviral vectors |
CA2675022A1 (en) * | 2007-01-09 | 2008-07-17 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
DK2222697T3 (da) | 2007-11-01 | 2013-03-11 | Perseid Therapeutics Llc | Immunsuppressive polypeptider og nukleinsyrer |
EP2250255A2 (en) * | 2008-03-04 | 2010-11-17 | The Trustees of the University of Pennsylvania | Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof |
JP5903045B2 (ja) * | 2009-07-31 | 2016-04-13 | パックスバックス, インコーポレイテッド | アデノウイルスに基づくベクター |
US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
US20120219583A1 (en) | 2009-10-16 | 2012-08-30 | Los Alamos National Security, Llc | Nucleic acid sequences encoding expandable hiv mosaic proteins |
WO2011057254A2 (en) | 2009-11-09 | 2011-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Simian adenoviral vector-based vaccines |
CA2779632C (en) | 2009-11-09 | 2019-08-20 | Jason Gall | Simian adenovirus and methods of use |
KR20180108886A (ko) | 2010-03-23 | 2018-10-04 | 인트렉손 코포레이션 | 치료적 단백질을 조건부로 발현하는 벡터,상기 벡터를 포함하는 숙주 세포 및 이의 용도 |
WO2011129468A1 (en) * | 2010-04-14 | 2011-10-20 | Mogam Biotechnology Research Institute | Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same |
US9862931B2 (en) * | 2010-04-28 | 2018-01-09 | Institut Gustave Roussy | Adenovirus vaccine vectors |
WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
WO2012083297A2 (en) | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions |
WO2012088041A1 (en) | 2010-12-20 | 2012-06-28 | Genvec, Inc. | Adenoviral vector-based dengue fever vaccine |
SG10201600912SA (en) | 2011-03-04 | 2016-03-30 | Intrexon Corp | Vectors conditionally expressing protein |
MX359518B (es) | 2012-04-18 | 2018-10-01 | Childrens Hospital Philadelphia | Composición y métodos para una transferencia génica altamente eficiente utilizando variantes de cápsides de aav. |
US9790519B2 (en) | 2012-05-29 | 2017-10-17 | Genvec, Inc. | Modified serotype 28 adenoviral vectors |
GB2510321B (en) * | 2012-11-12 | 2018-01-31 | Biosurgical S L | Agitation apparatus |
KR20150088841A (ko) * | 2012-11-25 | 2015-08-03 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 피하 지방생성을 자극하는 펩타이드 |
AU2014236207B2 (en) | 2013-03-14 | 2019-05-23 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
US10844102B2 (en) | 2014-05-28 | 2020-11-24 | The Regents Of The University Of California | Peptides, compositions, and methods for stimulating subcutaneous adipogenesis |
TWI710635B (zh) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
CN117384961A (zh) | 2016-02-23 | 2024-01-12 | 萨克生物研究学院 | 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达 |
CA3013637A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
WO2018064523A1 (en) | 2016-09-30 | 2018-04-05 | Genvec, Inc. | Adenovectors for delivery of therapeutic genetic material into t cells |
WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
KR20210093303A (ko) | 2018-11-21 | 2021-07-27 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 아데노바이러스 및 아데노바이러스의 사용 방법 |
WO2020172509A1 (en) | 2019-02-21 | 2020-08-27 | Unleash Immuno Oncolytics, Inc. | Oncolytic adenoviral vector and methods of use |
KR20210144818A (ko) | 2019-04-29 | 2021-11-30 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 암을 치료하기 위한 다가 pd-l1 결합 화합물 |
WO2023196550A2 (en) * | 2022-04-07 | 2023-10-12 | Regents Of The University Of Minnesota | Adenovirus constructs and methods of use |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4593002A (en) * | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins |
US4487829A (en) * | 1982-03-23 | 1984-12-11 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies against adenoviruses |
US4589881A (en) * | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
US4578079A (en) * | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4517686A (en) * | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
US4792525A (en) * | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4797368A (en) * | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
FR2602790B1 (fr) * | 1986-08-13 | 1990-06-01 | Transgene Sa | Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante |
EP0273085A1 (en) * | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US4956281A (en) * | 1987-06-03 | 1990-09-11 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3 |
US5024939A (en) * | 1987-07-09 | 1991-06-18 | Genentech, Inc. | Transient expression system for producing recombinant protein |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
JP2646013B2 (ja) * | 1988-09-14 | 1997-08-25 | 株式会社ジャパンエナジー | 抗ウイルス剤 |
CA2000048A1 (en) * | 1988-10-03 | 1990-04-03 | Edward F. Plow | Peptides and antibodies that inhibit integrin-ligand bindin g |
US5096815A (en) * | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5198346A (en) * | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
WO1990012087A1 (en) * | 1989-04-05 | 1990-10-18 | Novacell Corporation | Infectious targetted replication-defective virion |
US5223394A (en) * | 1989-04-10 | 1993-06-29 | Biogen, Inc. | Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence |
WO1991000360A1 (en) * | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5240846A (en) * | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5332567A (en) * | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
US5436146A (en) * | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
JPH05504677A (ja) * | 1989-10-20 | 1993-07-22 | トラスティーズ オブ ダートマス カレッジ | IgAレセプターに特異的なモノクロナール抗体 |
DE69032979T2 (de) * | 1989-10-20 | 1999-11-04 | Medarex Inc | Bispezifische heteroantikörper mit zweifachen effektorfunktionen |
AU7906691A (en) * | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US5246921A (en) * | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
GB2246779B (en) * | 1990-08-03 | 1994-08-17 | Delta Biotechnology Ltd | Tumour-associated protease inhibitors targeted to tumour cells |
WO1992006180A1 (en) * | 1990-10-01 | 1992-04-16 | University Of Connecticut | Targeting viruses and cells for selective internalization by cells |
GB9101550D0 (en) * | 1991-01-24 | 1991-03-06 | Mastico Robert A | Antigen-presenting chimaeric protein |
JP3534749B2 (ja) * | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
FR2681786A1 (fr) * | 1991-09-27 | 1993-04-02 | Centre Nat Rech Scient | Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires. |
NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
IL103059A0 (en) * | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
SE503225C2 (sv) * | 1991-10-30 | 1996-04-22 | Leif Lindholm Konsult Ab | Virus-antikroppskomplex för införing av virus i mammalieceller |
WO1993025234A1 (en) * | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
EP0670905B1 (en) * | 1992-09-22 | 2003-07-23 | Biofocus Discovery Limited | Recombinant viruses displaying a nonviral polypeptide on their external surface |
EP0669987B1 (en) * | 1992-09-25 | 2008-08-13 | Aventis Pharma S.A. | Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain |
GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
ATE307212T1 (de) * | 1992-11-18 | 2005-11-15 | Arch Dev Corp | Adenovirus-gelenkter gen-transfer zum herz-und glatten vaskulären muskel |
GB9300686D0 (en) * | 1993-01-15 | 1993-03-03 | Imp Cancer Res Tech | Compounds for targeting |
AU6133394A (en) * | 1993-02-09 | 1994-08-29 | Scripps Research Institute, The | Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton |
DE4311651A1 (de) * | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen |
AU6829994A (en) * | 1993-05-10 | 1994-12-12 | Regents Of The University Of Michigan, The | Gene transfer into pancreatic and biliary epithelial cells |
US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
WO1995006745A1 (de) * | 1993-09-03 | 1995-03-09 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Vektor für leber-gentherapie |
US5552311A (en) * | 1993-09-14 | 1996-09-03 | University Of Alabama At Birmingham Research Foundation | Purine nucleoside phosphorylase gene therapy for human malignancy |
US5534423A (en) * | 1993-10-08 | 1996-07-09 | Regents Of The University Of Michigan | Methods of increasing rates of infection by directing motion of vectors |
FR2712812B1 (fr) * | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
IT1271461B (it) * | 1993-12-01 | 1997-05-28 | Menarini Ricerche Sud Spa | Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso. |
US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US5928944A (en) * | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
US6312699B1 (en) * | 1994-03-28 | 2001-11-06 | Uab Research Foundation | Ligands added to adenovirus fiber |
US7252989B1 (en) * | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
EP0759087B1 (en) * | 1994-05-13 | 2001-03-28 | Chiron Corporation | Compositions and methods for targeting gene delivery vehicles |
US5571531A (en) * | 1994-05-18 | 1996-11-05 | Mcmaster University | Microparticle delivery system with a functionalized silicone bonded to the matrix |
FR2721943B1 (fr) * | 1994-06-29 | 1996-08-02 | Rhone Poulenc Rorer Sa | Adenovirus comprenant un gene codant pour une superoxyde dismutase |
US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
CA2199609A1 (en) * | 1994-09-09 | 1996-03-14 | Errol B. Desouza | Interleukin-1 type 3 receptors |
FR2724846B1 (fr) * | 1994-09-27 | 1996-12-20 | Rhone Poulenc Rorer Sa | Methode de traitement des cancers par regulation de l'activite des proteines ras |
AU704391B2 (en) * | 1994-10-28 | 1999-04-22 | Trustees Of The University Of Pennsylvania, The | Improved adenovirus and methods of use thereof |
WO1996014837A1 (en) * | 1994-11-09 | 1996-05-23 | Genetic Therapy, Inc. | Gene therapy for hypercholesterolemia |
EP0795606B1 (en) * | 1994-11-29 | 2000-08-16 | Takara Shuzo Co. Ltd. | Process for producing transformed cell |
FR2727867B1 (fr) * | 1994-12-13 | 1997-01-31 | Rhone Poulenc Rorer Sa | Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux |
US5770442A (en) * | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US5622699A (en) * | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
JP2001519647A (ja) * | 1995-12-28 | 2001-10-23 | カイロン コーポレイション | 標的細胞中へのウイルスおよび粒子の取り込みおよびインターナリゼーションのためのレセプター特異的キメラウイルス表面ポリペプチド |
CA2251738A1 (en) * | 1996-04-16 | 1997-10-23 | Immusol Incorporated | Targeted viral vectors |
US6210921B1 (en) * | 1996-09-13 | 2001-04-03 | Robert W. Finberg | CAR: a novel coxsackievirus and adenovirus receptor |
IL128958A0 (en) * | 1996-09-25 | 2000-02-17 | Novartis Ag And The Scripps Re | Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors |
US5877011A (en) * | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
DE19649645A1 (de) * | 1996-11-29 | 1998-06-04 | Hoechst Ag | Mehrfach funktionelles Ligandensystem zur zielzellspezifischen Übertragung von Nukleotidsequenzen |
US5922315A (en) * | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins |
-
1997
- 1997-03-13 US US08/816,346 patent/US6127525A/en not_active Expired - Lifetime
-
1998
- 1998-03-13 CA CA002283628A patent/CA2283628A1/en not_active Abandoned
- 1998-03-13 AU AU64652/98A patent/AU745252B2/en not_active Ceased
- 1998-03-13 EP EP98910401A patent/EP0973927A1/en not_active Withdrawn
- 1998-03-13 WO PCT/US1998/005033 patent/WO1998040509A1/en active IP Right Grant
- 1998-03-13 JP JP53987998A patent/JP2001517080A/ja active Pending
-
1999
- 1999-06-17 US US09/335,411 patent/US6153435A/en not_active Expired - Lifetime
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015057051A (ja) * | 2001-11-21 | 2015-03-26 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | サルアデノウイルス核酸およびアミノ酸配列、それを含むベクターおよび使用方法 |
JP2017070292A (ja) * | 2001-11-21 | 2017-04-13 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | サルアデノウイルス核酸およびアミノ酸配列、それを含むベクターおよび使用方法 |
JP2017035110A (ja) * | 2001-11-21 | 2017-02-16 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | サルアデノウイルス核酸およびアミノ酸配列、それを含むベクターおよび使用方法 |
JP2011055835A (ja) * | 2001-11-21 | 2011-03-24 | Trustees Of The Univ Of Pennsylvania | サルアデノウイルス核酸およびアミノ酸配列、それを含むベクターおよび使用方法 |
JP2015057052A (ja) * | 2001-11-21 | 2015-03-26 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | サルアデノウイルス核酸およびアミノ酸配列、それを含むベクターおよび使用方法 |
JP2009136296A (ja) * | 2001-11-21 | 2009-06-25 | Univ Pennsylvania | サルアデノウイルス核酸およびアミノ酸配列、それを含むベクターおよび使用方法 |
JP2017035111A (ja) * | 2001-11-21 | 2017-02-16 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | サルアデノウイルス核酸およびアミノ酸配列、それを含むベクターおよび使用方法 |
JP2012110326A (ja) * | 2004-01-23 | 2012-06-14 | Ist Di Ricerche Di Biologia Molecolare P Angeletti Spa | チンパンジーアデノウイルスワクチン担体 |
JP4843613B2 (ja) * | 2004-10-13 | 2011-12-21 | クルセル ホランド ベー ヴェー | 改良されたアデノウイルスベクターおよびその使用方法 |
JP2009523007A (ja) * | 2004-10-13 | 2009-06-18 | クルセル ホランド ベー ヴェー | 改良されたアデノウイルスベクターおよびその使用方法 |
JP2009535032A (ja) * | 2006-04-28 | 2009-10-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 改変アデノウイルスヘキソンタンパク質およびその用途 |
JP2018519847A (ja) * | 2015-05-04 | 2018-07-26 | ヴィーシーエヌ、バイオサイエンシズ、ソシエダッド、リミターダVcn Biosciences Sl | 免疫優性アデノウイルスエピトープに突然変異を有する腫瘍溶解性アデノウイルスおよび癌処置におけるそれらの使用 |
JP2021500899A (ja) * | 2017-10-31 | 2021-01-14 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | アデノウイルスベクター及びその用途 |
JP7229239B2 (ja) | 2017-10-31 | 2023-02-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | アデノウイルスベクター及びその用途 |
Also Published As
Publication number | Publication date |
---|---|
WO1998040509A1 (en) | 1998-09-17 |
AU6465298A (en) | 1998-09-29 |
EP0973927A1 (en) | 2000-01-26 |
US6153435A (en) | 2000-11-28 |
US6127525A (en) | 2000-10-03 |
AU745252B2 (en) | 2002-03-14 |
CA2283628A1 (en) | 1998-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001517080A (ja) | キメラアデノウイルスコート蛋白質およびその使用方法 | |
JP6639412B2 (ja) | アルブミン結合部分を含んでなるアデノウイルス | |
ES2256302T3 (es) | Vectores adenovirales para la transduccion de condrocitos. | |
US7235233B2 (en) | Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts | |
JPH08501703A (ja) | 欠陥組換えアデノウイルスベクター及び遺伝子治療での使用 | |
JP2001503250A (ja) | 束縛ペプチドモチーフを用いたターゲッティングアデノウイルス | |
JP2002531134A (ja) | 導入遺伝子の発現持続性を調節するためのトランス活性化およびシス活性化の使用 | |
JP2001510998A (ja) | 変更されたヘキソン蛋白質を有するアデノウィルス | |
JPH10505484A (ja) | 相補的なアデノウイルスベクター系と細胞系 | |
JPH11501219A (ja) | 細胞への遣伝子導入のためのベクターおよび方法 | |
CZ302895A3 (en) | The use of recombinant adenovirus of animal origin for preparing a pharmaceutical preparation | |
JP2000516098A (ja) | 短シャフトアデノウイルスファイバーおよびその用途 | |
JP2012139220A (ja) | 複製欠損アデノウイルスtnfベクター | |
CA2218610A1 (en) | An adenovirus helper-virus system | |
JP2015051018A (ja) | キメラアデノウイルスキャプシドタンパク質 | |
CN105755043B (zh) | 一种双拷贝人p53基因重组腺病毒及其制备方法 | |
US6867022B1 (en) | Replication deficient adenovirus vectors and methods of making and using them | |
KR100491299B1 (ko) | 개선된 질환 치료 효과를 갖는 재조합 아데노바이러스 및그를 포함하는 약제학적 조성물 | |
JP2002508661A (ja) | ウシアデノウイルスタイプ3ゲノム | |
Hauser et al. | Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy | |
Stratford-Perricaudet et al. | Gene therapy: the advent of adenovirus | |
JP2000157289A (ja) | 平滑筋細胞および/または内皮細胞への組織向性を与えられた遺伝子送達ベクタ― | |
AU2002212819B2 (en) | Adenoviral vectors for gene delivery in skeletal muscle cells or myoblasts | |
JP2005530495A (ja) | オールターナティブスプライシングされる核酸分子 | |
US7264818B2 (en) | BAV packaging regions and E1 transcriptional control regions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050311 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050311 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080129 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080430 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080616 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080529 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081202 |